Aptamer Sciences Inc Ordinary Shares 291650
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 291650 is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- —
- Day Range
- KRW 2,665.00–2,790.00
- 52-Week Range
- —–—
- Bid/Ask
- KRW 2,720.00 / KRW 2,750.00
- Market Cap
- KRW 46.70 Bil
- Volume/Avg
- 31,351 / 194,787
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 192.02
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aptamer Sciences Inc is a research and development based bio venture company. The company is focused on the Aptamer Technology Platform for the development of innovative therapeutic and diagnostic platforms. It develops and facilitates drug development and other diagnostic products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 41
- Website
- http://www.aptsci.com
Comparables
Valuation
|
Metric
|
291650
|
228760
|
314930
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.32 | 4.32 | 6.01 |
Price/Sales | 192.02 | 143.87 | 66.75 |
Price/Cash Flow | — | — | — |
Price/Earnings
291650
228760
314930
Financial Strength
|
Metric
|
291650
|
228760
|
314930
|
|---|---|---|---|
Quick Ratio | 1.58 | 17.76 | 33.73 |
Current Ratio | 1.64 | 18.06 | 35.00 |
Interest Coverage | −9.53 | −5.57 | −8,694.04 |
Quick Ratio
291650
228760
314930
Profitability
|
Metric
|
291650
|
228760
|
314930
|
|---|---|---|---|
Return on Assets (Normalized) | −31.70% | −5.18% | −2.51% |
Return on Equity (Normalized) | −59.14% | −6.67% | −2.56% |
Return on Invested Capital (Normalized) | −40.39% | −7.80% | −3.88% |
Return on Assets
291650
228760
314930
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bxlknqhtp | Rmgxg | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dgqhkhtvc | Mmhxj | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jtmsxvvzz | Hsrvgfx | $97.8 Bil | |
MRNA
| Moderna Inc | Xydqpfbd | Thqg | $41.3 Bil | |
ARGX
| argenx SE ADR | Gdgghdf | Zgjm | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Kqzvwbcx | Msw | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Frjtzvhw | Zsjrwmj | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vdkcjmnqq | Wcywdj | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mtryxvgcgx | Wrrzc | $12.5 Bil | |
INCY
| Incyte Corp | Ppwcnzrz | Blhkp | $11.6 Bil |